Beijing Tiantan Biological Products Co., Ltd.
5
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.5% vs industry average
60%
3 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients
Role: collaborator
Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine
Role: collaborator
Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine
Role: collaborator
Study of Evaluating Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine
Role: collaborator
A Post-marketing Safety Study of Beijing Tiantan Biological's Influenza Virus Vaccine in Elderly
Role: collaborator
All 5 trials loaded